New combo therapy aims to halt prostate cancer spread

NCT ID NCT03795207

Ongoing Disease control Sponsor: Institut Cancerologie de l'Ouest Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests whether adding the immunotherapy drug durvalumab to precise radiation (SBRT) can better control prostate cancer that has returned and spread to a few spots (oligometastases). About 96 men with hormone-sensitive prostate cancer will be randomly assigned to receive SBRT alone or SBRT plus durvalumab for up to 12 months. The main goal is to see if the combination delays cancer progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Durvalumab (an immunotherapy drug) and stereotactic body radiation therapy (SBRT, a precise high-dose radiation procedure)
What this could lead to: If successful, this could offer a new treatment option that delays cancer progression in men with a limited number of prostate cancer metastases.
What could go wrong: This is a phase II trial with only 96 participants, so results are preliminary. Adding immunotherapy to radiation may increase side effects, and the combination might not improve outcomes over radiation alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BONE METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic carcinoma in the bone metastatic prostate carcinoma prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BONE METASTASES NODE; PROSTATE PROSTATE CANCER PATIENTS

Contacts and locations

Locations

CHRU de Brest

Brest, 29200, France
Centre Georges François Leclerc

Dijon, 21079, France
Centre Léon Bérard

Lyon, 69373, France
Centre Oscar Lambret

Lille, 59020, France
Chbs Lorient

Lorient, 56100, France
Hospices Civils de Lyon

Pierre-Bénite, 69310, France
ICO

Saint-Herblain, 44805, France
Institut Bergonie

Bordeaux, 33076, France
Institut de Cancérologie de Montpellier

Montpellier, 34298, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.